315 related articles for article (PubMed ID: 20138761)
1. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
2. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors.
Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
Bioorg Med Chem Lett; 2010 May; 20(9):2765-9. PubMed ID: 20378346
[TBL] [Abstract][Full Text] [Related]
5. 5-amino-pyrazoles as potent and selective p38α inhibitors.
Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
7. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
[TBL] [Abstract][Full Text] [Related]
8. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
[TBL] [Abstract][Full Text] [Related]
9. Identification of triazolopyridazinones as potent p38α inhibitors.
Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
[TBL] [Abstract][Full Text] [Related]
11. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.
Wu B; Wang HL; Pettus L; Wurz RP; Doherty EM; Henkle B; McBride HJ; Saris CJ; Wong LM; Plant MH; Sherman L; Lee MR; Hsieh F; Tasker AS
J Med Chem; 2010 Sep; 53(17):6398-411. PubMed ID: 20712346
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1.
Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
Bioorg Med Chem Lett; 2011 Jan; 21(1):411-6. PubMed ID: 21084192
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
[TBL] [Abstract][Full Text] [Related]
14. 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.
Lumeras W; Vidal L; Vidal B; Balagué C; Orellana A; Maldonado M; Domínguez M; Segarra V; Caturla F
J Med Chem; 2011 Nov; 54(22):7899-910. PubMed ID: 21999461
[TBL] [Abstract][Full Text] [Related]
15. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA
J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819
[TBL] [Abstract][Full Text] [Related]
16. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619
[TBL] [Abstract][Full Text] [Related]
17. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
18. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS
J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364
[TBL] [Abstract][Full Text] [Related]
19. A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.
Kirkwood KL; Li F; Rogers JE; Otremba J; Coatney DD; Kreider JM; D'Silva NJ; Chakravarty S; Dugar S; Higgins LS; Protter AA; Medicherla S
J Pharmacol Exp Ther; 2007 Jan; 320(1):56-63. PubMed ID: 17041006
[TBL] [Abstract][Full Text] [Related]
20. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
